117 related articles for article (PubMed ID: 7685864)
1. Effects of benzylpiperazine derivatives on the acute effects of 3,4-methylenedioxymethamphetamine in rat brain.
Hashimoto K
Neurosci Lett; 1993 Apr; 152(1-2):17-20. PubMed ID: 7685864
[TBL] [Abstract][Full Text] [Related]
2. Effects of benzylpiperazine derivatives on the neurotoxicity of 3,4-methylenedioxymethamphetamine in rat brain.
Hashimoto K; Maeda H; Goromaru T
Brain Res; 1992 Sep; 590(1-2):341-4. PubMed ID: 1384935
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of 3,4-methylenedioxymethamphetamine-induced neurotoxicity in rat brain by 1-piperonylpiperazine.
Hashimoto K; Maeda H; Goromaru T
Eur J Pharmacol; 1992 Sep; 228(2-3):171-4. PubMed ID: 1280228
[TBL] [Abstract][Full Text] [Related]
4. 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents.
Hekmatpanah CR; Peroutka SJ
Eur J Pharmacol; 1990 Feb; 177(1-2):95-8. PubMed ID: 1971219
[TBL] [Abstract][Full Text] [Related]
5. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.
Colado MI; Murray TK; Green AR
Br J Pharmacol; 1993 Mar; 108(3):583-9. PubMed ID: 7682129
[TBL] [Abstract][Full Text] [Related]
6. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain.
Steele TD; Nichols DE; Yim GK
Biochem Pharmacol; 1987 Jul; 36(14):2297-303. PubMed ID: 2886126
[TBL] [Abstract][Full Text] [Related]
7. Reduction of [3H]6-nitroquipazine-labelled 5-hydroxytryptamine uptake sites in rat brain by 3,4-methylenedioxymethamphetamine.
Hashimoto K; Goromaru T
Fundam Clin Pharmacol; 1990; 4(6):635-41. PubMed ID: 1710592
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
[TBL] [Abstract][Full Text] [Related]
9. In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3,4-methylenedioxymethamphetamine.
Murphy J; Flynn JJ; Cannon DM; Guiry PJ; McCormack P; Baird AW; McBean GJ; Keenan AK
Eur J Pharmacol; 2002 May; 444(1-2):61-7. PubMed ID: 12191583
[TBL] [Abstract][Full Text] [Related]
10. [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues.
Johnson MP; Conarty PF; Nichols DE
Eur J Pharmacol; 1991 Jul; 200(1):9-16. PubMed ID: 1685125
[TBL] [Abstract][Full Text] [Related]
11. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.
O'Shea E; Esteban B; Camarero J; Green AR; Colado MI
Neuropharmacology; 2001; 40(1):65-74. PubMed ID: 11077072
[TBL] [Abstract][Full Text] [Related]
12. In vitro release of [3H]5-hydroxytryptamine from fetal and maternal brain by drugs of abuse.
Kramer K; Azmitia EC; Whitaker-Azmitia PM
Brain Res Dev Brain Res; 1994 Mar; 78(1):142-6. PubMed ID: 7911745
[TBL] [Abstract][Full Text] [Related]
13. Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors.
Schmidt CJ; Taylor VL
Eur J Pharmacol; 1990 May; 181(1-2):133-6. PubMed ID: 1974853
[TBL] [Abstract][Full Text] [Related]
14. Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.
Durkin S; Prendergast A; Harkin A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1894-901. PubMed ID: 18824064
[TBL] [Abstract][Full Text] [Related]
15. Effect of 3,4-methylenedioxymethamphetamine on [3H]paroxetine binding in the frontal cortex and blood platelets of rats.
Nash JF; Arora RC; Schreiber MA; Meltzer HY
Biochem Pharmacol; 1991 Jan; 41(1):79-84. PubMed ID: 1702633
[TBL] [Abstract][Full Text] [Related]
16. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats.
Mechan AO; Esteban B; O'Shea E; Elliott JM; Colado MI; Green AR
Br J Pharmacol; 2002 Jan; 135(1):170-80. PubMed ID: 11786492
[TBL] [Abstract][Full Text] [Related]
17. 5-HT, MDMA (ecstasy), and nimodipine effects on 45Ca-uptake into rat brain synaptosomes.
Park WK; Azmitia EC
Ann N Y Acad Sci; 1991; 635():438-40. PubMed ID: 1683755
[No Abstract] [Full Text] [Related]
18. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine.
McKenna DJ; Guan XM; Shulgin AT
Pharmacol Biochem Behav; 1991 Mar; 38(3):505-12. PubMed ID: 1829838
[TBL] [Abstract][Full Text] [Related]
19. Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs.
Schmidt CJ
Eur J Pharmacol; 1987 Apr; 136(1):81-8. PubMed ID: 2885204
[TBL] [Abstract][Full Text] [Related]
20. The neurochemical and stimulatory effects of putative metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in rats.
Yeh SY; Hsu FL
Pharmacol Biochem Behav; 1991 Jul; 39(3):787-90. PubMed ID: 1723801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
